Showing results (211-220 of 432) with videos related to

Sort By:
Pageof 44
The Journal of Infectious Diseases|August 1, 2023
Decay of HIV RNA in Seminal Plasma and Rectal Fluid in Treatment-Naive Adults Starting Antiretroviral Therapy With Dolutegravir Plus Lamivudine or Bictegravir/Emtricitabine/Tenofovir AlafenamideSofía Scévola, Jordi Niubó, Pere Domingo, et al.
Life Sciences|September 12, 2022
Differential effects of dolutegravir, bictegravir and raltegravir in adipokines and inflammation markers on human adipocytesPere Domingo, Tania Quesada-López, Joan Villarroya, et al.
AIDS Research and Human Retroviruses|December 28, 2007
A lopinavir/ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeksJean-Michel Molina, Thomas J Podsadecki, Margaret A Johnson, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 9, 2013
Dynamics of CD8 T-cell activation after discontinuation of HIV treatment intensificationMarta Massanella, Anna Esteve, Maria J Buzón, et al.
The Journal of Antimicrobial Chemotherapy|December 22, 2016
Switching from a ritonavir-boosted PI to dolutegravir as an alternative strategy in virologically suppressed HIV-infected individualsEugènia Negredo, Vicente Estrada, Pere Domingo, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|August 24, 2015
Prediction of higher cost of antiretroviral therapy (ART) according to clinical complexity. A validated clinical indexCesar Velasco, Inaki Pérez, Daniel Podzamczer, et al.
Antiviral Therapy|June 21, 2011
HBV primary drug resistance in newly diagnosed HIV-HBV-coinfected individuals in SpainPaula Tuma, Juan Antonio Pineda, Pablo Labarga, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|January 12, 2015
[Barriers to ART initiation in HIV infected subjects and with treatment indication in Spain. Why don't they start their treatment? Bridgap Study]Pompeyo Viciana-Fernández, Vicenç Falcó, Manuel Castaño, et al.
HIV Clinical Trials|December 23, 2011
Effect of baseline characteristics on the efficacy and safety of once-daily darunavir/ ritonavir in HIV-1-infected, treatment-naïve ARTEMIS patients at week 96Jan Fourie, Jason Flamm, Amalia Rodriguez-French, et al.
European Journal of Clinical Investigation|November 16, 2024
Blood CD45<sup>+</sup>/CD3<sup>+</sup> lymphocyte-released extracellular vesicles and mortality in hospitalized patients with coronavirus disease 2019Rosa Suades, Maria F Greco, Teresa Padró, et al.
Pageof 44